Beijing, Aug 30, 2026 — China’s National Medical Products Administration cleared 49 batches of biological products for market distribution during the week ended Aug 30, 2026, spanning vaccines, blood products, and diagnostic reagents from major domestic manufacturers and one imported supplier.
Batch Release Summary
| Category | Key Products | Notable Manufacturers |
|---|---|---|
| Vaccines | 13-valent pneumococcal conjugate; ACYW135 meningococcal conjugate; A/C meningococcal conjugate; EV71 inactivated; hepatitis A live attenuated; rabies (Vero cell and human diploid cell); oral polio type I/III; pentavalent rotavirus; influenza subunit; DTaP | CanSinoBIO; Chengdu Olymvax; Walvax; CAMS; Changchun Institute; Changchun Zhuoyi; Chengdu Kanghua; Beijing Institute; Merck Sharp & Dohme; Jiangsu Zhonghui Yuan Tong; Chengdu Institute |
| Blood Products | Human coagulation Factor VIII; human fibrinogen | Shanghai RAAS Blood Products |
| Diagnostics | Syphilis TRUST; syphilis TP antibody ELISA; HIV antibody ELISA; HIV antigen/antibody ELISA | InTec Xiamen; Shanghai Kehua Bio-engineering |
Market Impact Analysis
The batch release underscores steady supply chain momentum across China’s biological product sector heading into the autumn vaccination season. CanSinoBIO secured approvals for multiple conjugate vaccine batches, including its 13-valent pneumococcal vaccine and ACYW135 meningococcal vaccine, reinforcing the company’s position in China’s expanding pediatric and adolescent immunization market. The inclusion of Merck Sharp & Dohme’s imported pentavalent rotavirus vaccine batches highlights continued reliance on foreign suppliers for select pediatric vaccines despite domestic capacity expansion.
Shanghai RAAS maintained its dominance in the plasma-derived therapeutics segment with Factor VIII and fibrinogen batches cleared, ensuring continuity of care for hemophilia and coagulation disorder patients. The diagnostic reagent releases—covering syphilis and HIV screening—support routine clinical and blood bank testing demand.
Forward-Looking Statement
Industry analysts expect the weekly batch release cadence to accelerate through September as manufacturers ramp production ahead of the national immunization program’s autumn campaign and flu season procurement. The strong showing of conjugate vaccines from CanSinoBIO and meningococcal products from multiple suppliers suggests adequate inventory for school-entry vaccination drives. Blood product batch volumes remain consistent with historical patterns, though ongoing plasma collection constraints may limit significant supply expansion through year-end.-China Health Reform Pulse
Policy Source: https://www.nifdc.org.cn/directory/web/nifdc/xxgk/ggtzh/jwgk/shwzhppfgg/202609011454062187203.html